Evercore ISI Group Rates Inspire Medical Systems (INSP) hold

Evercore ISI Group has downgraded INSP to a hold rating with a new price target of $40, a 7.41% downside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 10:01 AM EDT · Updated Jun 26, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Evercore ISI Group rated Inspire Medical Systems, Inc. ($INSP) "hold" with a $40 price target on June 23, 2026.

Since the rating, $INSP is up 6.8% after 1 week, up 21.7% after 1 month and up 64.8% to date (from the $41.75 close on Jun 23, 2026).

INSP Inspire Medical Systems, Inc.

$68.79 -25.45% year to date

Daily close · Oct 16, 2026

Key Points

Evercore ISI Group downgraded INSP to a hold rating on June 23, setting a new price target of $40.
Evercore ISI Group's $40 price target implies 7.41% downside from Inspire Medical Systems, Inc.'s ($INSP) current $43.20 share price.
Shares of INSP traded at $41.35 on Tuesday, reflecting the recent analyst update.
Recent institutional moves include Deerfield Management increasing its stake by 79.5% and Vanguard Capital opening a new position.

Get $INSP trade alerts by text

We text you when insiders, Congress or big funds trade $INSP. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Inspire Medical Systems, Inc. alert may contain errors. Disclosures

Evercore ISI Group has adjusted its outlook on INSP, downgrading the stock to a hold rating on June 23, 2026. Analyst Daniel Markowitz set a new price target of $40, signaling a more cautious view compared to previous expectations.

Analyst rating track record

Evercore ISI Group vs. the S&P 500

YTD return +14.46% hypothetical

All-time return +27.58% S&P 500 +28.06%

vs. S&P 500 -0.48% behind the index

Hypothetical returns from Evercore ISI Group's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in INSP

Several major funds have also adjusted their positions in INSP. Deerfield Management Company significantly increased its holdings by 1,197,366 shares, now holding a total of 2,703,238 shares valued at about $139.4 million, marking a 79.5% increase. Wellington Management Group added 324,863 shares, bringing its total to 2,535,954 shares worth approximately $130.8 million, a 14.7% increase. Vanguard Portfolio Management LLC opened a new position with 1,637,173 shares valued at around $84.4 million. Meanwhile, Morgan Stanley increased its position by 190,872 shares, now holding 1,450,634 shares valued at $74.8 million, a 15.2% increase.

Inspire Medical Systems, Inc. Stock Down 43.7%

Shares of INSP traded near $41.35 on Tuesday. The stock has experienced a range of institutional activity, as reflected in the recent updates from major funds and analysts.

12-month forecast

$INSP price target

Inspire Medical Systems, Inc. daily closes and this analyst's $40 target. Not advice.

Insider Buying and Selling at Inspire Medical Systems, Inc.

Recent insider activity at INSP includes several sales by insiders. Chief Product and Innovation Officer John Rondoni sold 2,641 shares on May 15, 2026, at an average price of $43.28, and 700 shares on May 14, 2026, at $43.01. Shawn McCormick sold 696 shares on May 8, 2026, at $45.31 as part of a planned transaction. Georgia Melenikiotou sold 50 shares on May 1, 2026, at $56.70. On the buying side, Gary Lee Ellis and Cynthia Burks each purchased 3,562 shares on April 30, 2026.

Analysts Set New Price Targets

On June 23, 2026, Evercore ISI Group downgraded INSP to a hold rating, setting a price target of $40. Previously, on May 5, 2026, JP Morgan maintained a hold rating with a $54 target, while Piper Sandler downgraded the stock to a hold with a $55 target. Stifel maintained a buy rating with a $65 price target, and RBC Capital kept its hold rating with a $45 target.

Bottom Line

Evercore ISI's recent downgrade and adjusted price target for INSP highlight a more cautious stance on the stock. This change comes amid various institutional adjustments and insider transactions, offering a mixed picture of market sentiment. Investors often track these updates to gauge potential future performance, keeping in mind that analyst ratings and 13F filings are backward-looking and may not reflect current conditions.